MORE►
Alzheimer’s disease
[Image: sudok1/istockphoto]
Alpha Cognition Launches Sales of Alzheimer’s Drug ZUNVEYL
by David Seeley | Mar 18, 2025
"The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease," said Lauren D’Angelo, COO and chief commercial officer at Alpha Cognition. The drug is designed to provide "a differentiated treatment option" for patients with mild-to-moderate Alzheimer’s diagnoses.
by David Seeley |
Jan 9, 2025
Alpha Cognition’s Alzheimer’s oral therapy ZUNVEYL, FDA-approved in July, targets U.S. launch in Q1 2025 as the company boosts its commercialization team with five new hires.
MORE►
by Lance Murray |
Nov 5, 2024
UTD psychology professors Karen Rodrigue and Kristen Kennedy will use one of the most powerful imaging machines in existence—the 24-ton 7-Tesla magnetic resonance scanner—to identify the major brain differences between younger and older adults.
MORE►
by Lance Murray |
Jul 29, 2024
“The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha Cognition. Based in Vancouver with an office in Frisco, the company was honored at the 2023 BioNTX iC3 Summit as one of eight "Rising Stars."
MORE►
[Image: peterschreiber.media/istockphoto]
AI Can Detect Early Signs of Alzheimer’s in How People Speak, New Study Shows
by David Seeley | Apr 17, 2023
Subtle changes in the way people speak could help doctors diagnose cognitive impairment and Alzheimer’s disease—even before symptoms begin to show. That's according to a new study led UT Southwestern researcher Ihab Hajjar, M.D., working with a research team at Emory University in Atlanta. After being given standard cognitive assessments, 206 participants were asked to talk about an art work. Here's what happened next.
MORE►
by Lance Murray |
Mar 9, 2023
Rebelution CEO Melonie Carnegie will chair the fourth annual Gala, An Event to Remember, hosted by the Dallas and Northeast Texas Chapter of the Alzheimer’s Association on April 29 at the Arts District Mansion....
MORE►
by Lance Murray |
Jan 27, 2023
The foundation—launched in the early 1990s by Fort Worth billionaire and philanthropist Richard E. Rainwater—said that this year's $400K Outstanding Innovation Prize will be awarded to a team from the University of California San Diego and Washington University.
Dr. Susanne Wegmann of the German Center for Neurodegenerative Diseases (DZNE) will be awarded the $200K Rainwater Prize for Innovative Early-Career Scientist.
MORE►
by David Seeley |
Jan 18, 2023
Frisco-based pharmacy services provider Soleo Health has been selected by Eisai Inc. as the sole specialty pharmacy distribution partner for Leqembi (lecanemab-irmb), a newly FDA-approved treatment for early and mild stages of Alzheimer’s Disease.
Soleo Health CEO Drew Walk says the partnership "will afford the Alzheimer’s community continued hope while we assist patients and their caregivers as they navigate their healthcare journey."
MORE►
Sid O’Bryant
This HSC Professor is Working To Fundamentally Change the Way Alzheimer’s Disease is Diagnosed and Treated
by Sandra Engelland | Mar 16, 2021
Contracting Alzheimer's is the No. 1 fear of people over 65, says Sid O'Bryant, who wants to give primary physicians the ability to test for Alzheimer's with a blood test. That can offer peace of mind to many and earlier help for those who need it.
His groundbreaking research, which has revealed significant differences in biomarkers for the disease, could make the treatment of Alzheimer's more like that for cancer—a multi-dimensional "precision" approach.
His groundbreaking research, which has revealed significant differences in biomarkers for the disease, could make the treatment of Alzheimer's more like that for cancer—a multi-dimensional "precision" approach.
MORE►
by Lance Murray |
Sep 20, 2019
In this weekly roundup of research and development activity in North Texas, you'll also find news about a UT Southwestern study on how exercise may slow brain deterioration for those at risk of Alzheimer's disease.
MORE►
by Lance Murray |
Jan 25, 2019
You’ll also find out about how research at the University of Texas at Dallas may help determine who is at high risk for Alzheimer’s disease in this roundup of research and development activity in North Texas.
MORE►
![R&D: UTA Professor's Quest to Unify Storm Forecasts; UTSW Studies 'Couch Potato' Behavior Photo: Igor Zhuravlov/iStock]](https://s24806.pcdn.co/wp-content/uploads/2016/09/Verizon-tornado-970-iStock_IgorZhuravlov-360x203.jpg)
by Lance Murray |
Jan 11, 2019
In this roundup of research and development work going on in North Texas, you'll also learn about a $3M gift to the UNT Health Science Center that will fund an endowed chair and benefit Alzheimer's research.
MORE►
[Illustration by SiberianArt via iStock]
R&D: $200K Grant Aids UTA Reabsorbable Brain Implant Work; Will UTD Chess Computing Platform Say Checkmate?
by Lance Murray | Nov 9, 2018
Also, you'll learn about the Dallas-based American Heart Association backing research teams looking into age-related cognitive declines, and a Plano-based biotech company getting an approval from the EPA.
MORE►
by Lance Murray |
Oct 26, 2018
Also, you'll learn about how two schools are splitting a National Cancer Institute grant to study cancer health disparity and how TWU plans to show off its research. Here are some of the research projects underway in North Texas that could make lives better.
MORE►
by Lance Murray |
Oct 5, 2018
Also, you'll learn about a researcher who's studying the effects of even mild traumatic brain injuries on veterans. Here are some of the research projects underway in North Texas that could make lives better.
MORE►
by Lance Murray |
Jul 13, 2018
Also, you'll find research on how a UTA professor is looking to optimize the national power grid. Here are some of the research projects underway in North Texas aimed at making our lives better.
MORE►
